AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia.

CONCLUSIONS: AMG-176 is active in inducing CLL cell death while sparing normal blood cells. Combination with low dose venetoclax had at least additive effect.
PMID: 31937611 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 13, 2020 Category: Cancer & Oncology Authors: Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda W, Long JP, Bertilaccio MTS, Gandhi V Tags: Clin Cancer Res Source Type: research